Porustobart in combination with toripalimab showed promising anti-tumor activity in advanced high-grade neuroendocrine neoplasms (NENs) The ORR and DCR were 38.5% and 69.2% in neuroendocrine carcinoma (NEC) patients The results showed great potential to develop porustobart as a…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.